CompletedNCT00690235
Pramlintide or placebo for weight gain linked to schizophrenia medicines
About this title
Read the official source — NCT00690235Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- DallasSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNovember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 33
- Sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00690235
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Effects of Pramlintide on Weight Reduction in Clozapine- and Olanzapine-Induced Weight Gain in Obese People Diagnosed With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Dallas
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Texas Southwestern Medical Center, a university.
Did this study involve medication?
Yes. The study involved medication, including Pramlintide and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
